Fleury S A : Results Presentation - 2Q23

2Q23 Earnings

August 04th, 2023

2

D I S C L A I ME R

Disclaimer

This presentation may contain information about future events. Such information is not just historical facts, but would reflect the wishes and expectations of the company's management.

The words "believe", "expect", "plan", "anticipate", "estimate", "project", "aim" and the like are intended to identify statements that necessarily involve known and unknown risks. Known risks include uncertainties, which are not limited to the impact of price and service competitiveness, market acceptance of services, company and competitor service transactions, regulatory approval, currency fluctuation, changes in the mix of services offered and other risks. described in the company's reports.

Additional unaudited or audited information contained herein reflects the interpretation of the Company's Management on information derived from its financial statements and their respective adjustments, which were prepared in accordance with market practices and for the exclusive purpose of a more detailed and specific analysis. of the Company's results. Therefore, such considerations and additional data must also be analyzed and interpreted independently by shareholders and market agents, who must make their own analyzes and conclusions on the information disclosed herein. No data or interpretative analysis carried out by the Company's Management should be treated as a guarantee of performance or future results and are merely illustrative of the Company's Management's view of its results.

The Company's Management is not responsible for the compliance and accuracy of the information discussed in this report. Such information should be considered for informational purposes only and not as a substitute for analyzing our audited or audited consolidated financial statements for the purpose of an investment decision in our shares, or for any other purpose.

This presentation is up to date and Grupo Fleury is not obliged to update it in light of new information and/or future events.

All comparisons made are relative to the same period of the previous year, unless otherwise specified.

NOME APRESENTAÇÃO	SAO

Overview

Agenda

Lab-to-Lab

Financial Highlights

Overview

5

O V E R V I EW

Integration of the Patient's Journey

B2C + B2B

		Diagnostics
Prevention	Primary Care	Secundary Care
Check-ups			Infusion
		Telemedicine
Vaccines			Orthopedics
		Appointments	Ophthalmics
Genomics
			Fertility
Other	Tech Platforms
Initiatives	Joint Ventures	G enom i cs: +	H o s p i t a l I s r a e l i t a	Oncology: +
	A l b e r t E i n s t e i n

Tertiary Care

Ambulatorial

Surgical Center

Hospitals in the

Platform

B e n e f i c i ê n c i a	+
P o r t u g u e s a

NOME APRESENTAÇÃO	SAO